【摘 要】
：
NIFEVIROC,a small molecular compound,is a proprietary drug candidate which is developed by TARGETDRUG and holds great promise in inhibiting HIV-1 replicatio
【机 构】
：
CEOShanghaiTargetDrugCo.,Ltd,Shanghai,China
【出 处】
：
2006中国天津世界艾滋病日科技会议
论文部分内容阅读
NIFEVIROC,a small molecular compound,is a proprietary drug candidate which is developed by TARGETDRUG and holds great promise in inhibiting HIV-1 replication in infected patients.Preclinical studies suggested that NIFEVIROC is a specific CCR5 antagonist determined by multiple receptor functional assays.In addition,NIFEVIROC demonstrated potent inhibition activity against HIV-1 entry into the target cells by effectively blocking the human CCR5 receptors on the cell membrane.Furthermore,NIFEVIROC showed strong antiviral activity against wide variety of HIV strains,including those multi-drug resistant mutants.Pharmacokinetic studies confirmed the oral bioavailability of NIFEVIROC,and its safety in various animal models in both acute and chronic states.
其他文献
The face of HIV/AIDS is changing.Increasingly,it is a womans face.Six out often new HIV infections are now among women.Womens physiology makes them more vul
Since the discovery of HIV,the causative agent of AIDS,important advances in this field have been made:prevention of the transmission of the agent by blood
The small protein ubiquitin is covalently attached to many cellular proteins in an energy-dependent process.Depending upon the mode of ubiquitin linkage,pro
Resistance of vertebrate hosts against infections comprises important natural of innate immunity combined with adaptive immune responses ofT and B ceils.Vir
Interferon (IFN) was discovered in 1957 and was defined as an antiviral substance.However,people can not get enough IFN materials for research or clinical t
MolecularBreeding? directed molecular evolution expands naturally occurring diversity and allows the identification of protein variants with desirable prope
Historically,the macaque model of HIV pathogenesis has involved use of simian immunodeficiency virus,SIV,and simian human immunodeficiency virus,SHIV.SIV,ex
The development of a prophylactic vaccine to control the HIV pandemic remains a major critical challenge facing the global public health.With more than 40 m